Ryman Healthcare AI Stock Analysis
Want to see NZ:RYM full AI Analyst Report?
Ryman Healthcare (RYM) AI Stock Analysis
Ryman Healthcare
(NZX:RYM)
The score is supported primarily by improving cash generation and constructive earnings-call guidance around cost-out, balance-sheet strengthening, and disciplined development spending. Offsetting this are weak and volatile profitability (recent large losses) and bearish technical signals with the stock trading below major moving averages; valuation is also constrained by loss-making results (negative P/E) and no provided dividend yield.
Ryman Healthcare (RYM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- NZD 992.80M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.93M
- Price to Earnings (P/E)
- -11.2
- Beta (1Y)
- 1.74
- Revenue Growth
- 11.86%
- EPS Growth
- 72.99%
- Country
- NZ
- Employees
- 7,800
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Ryman Healthcare Business Overview & Revenue Model
Company Description
Ryman Healthcare Limited, established in Christchurch, New Zealand, in 1984, specializes in the development, ownership, and management of all-encompassing retirement communities for seniors. Operating across both New Zealand and Australia, the compan...
How the Company Makes Money
Ryman makes money primarily through its integrated retirement village and aged-care model. A core revenue stream comes from selling occupation rights to residents (commonly structured as an occupation right agreement rather than a freehold sale), whe...
Ryman Healthcare Earnings Call Summary
The call reported clear operational progress: doubled operating EBITDAF, strong aged-care performance (EBITDAF per bed +31%), significant cost savings ($57m), positive free cash flow of $188m, reduced development exposure and a strengthened balance sheet (refinancing, lower interest costs). Management acknowledges remaining challenges — resale stock and margins, timing of DMF cash benefits, one-off transformation costs, FX effects and regional market competitiveness — and provided targets and actions (sales/marketing investment, land divestments, product changes, and a $150m CFEO improvement target to FY'29). Overall the positives — particularly cash generation, cost-out, and aged care momentum — materially outweigh the current lowlights, supporting a constructive outlook while risks from market conditions and timing remain.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Ryman’s guidance emphasizes cash generation, disciplined development and growing care earnings: management is targeting to lift retirement‑living resales to match turnover by end FY'27, expects lower FY'27 build and CapEx with only 2 active construction sites and ~50% of FY'27 development CapEx already locked (committed cost‑to‑go on main buildings ~$190m), and is prioritising care where EBITDAF per bed is targeted at $25,000–$30,000 by FY'29 (H2 FY'26 was $20,200/bed; FY'26 country run‑rates were NZD15,000 in NZ and ~NZD32,000 in AU). Medium‑term financial targets remain a $150m improvement in sustainable CFEO by FY'29 (already $47m achieved in year one) and a $500m cash‑release program (FY'26 delivered $169m, with a further $75m locked in and $147m of land sales contracted — $72m cash received to date; management has raised the land‑divestment ambition to ~ $250m), plus targets to reduce normalized non‑village costs to < $100m by FY'29. Balance‑sheet guidance: FY'26 free cash flow was $188m, net debt $1.57bn with $675m facility headroom, gearing <28%, and average cost of debt ~5.9% (annualized gross interest down $68m since Feb‑2025).
Ryman Healthcare Financial Statement Overview
Summary
Cash flow is the main strength (positive OCF/FCF across years with strong FY26 FCF improvement), and the balance sheet shows moderate leverage and sizable equity. However, the income statement is a major drag: despite steady revenue growth, profitability has deteriorated into large losses in FY25–FY26 with negative operating profit, keeping the overall financial score in the mid-range.
Income Statement
34NegativeBalance Sheet
58NeutralCash Flow
72Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 798.49M | 798.49M | 713.80M | 650.53M | 560.11M | 503.76M |
| Gross Profit | -17.76M | -17.76M | 713.80M | -1.35M | -19.77M | 1.82M |
| EBITDA | 50.49M | 24.79M | -27.16M | -48.55M | 264.80M | 788.44M |
| Net Income | -171.34M | -171.34M | -436.83M | 4.78M | 257.84M | 692.87M |
Balance Sheet | ||||||
| Total Assets | 12.27B | 12.27B | 12.06B | 13.08B | 12.51B | 10.97B |
| Cash, Cash Equivalents and Short-Term Investments | 9.70M | 9.70M | 17.66M | 41.81M | 27.88M | 28.31M |
| Total Debt | 1.59B | 1.59B | 1.70B | 2.57B | 2.34B | 2.59B |
| Total Liabilities | 8.19B | 8.19B | 7.80B | 8.67B | 7.85B | 7.53B |
| Stockholders Equity | 4.08B | 4.08B | 4.26B | 4.42B | 4.66B | 3.43B |
Cash Flow | ||||||
| Free Cash Flow | 272.38M | 272.38M | 302.89M | 486.28M | 218.55M | 237.34M |
| Operating Cash Flow | 319.68M | 319.68M | 410.25M | 658.48M | 542.76M | 535.97M |
| Investing Cash Flow | -133.32M | -133.32M | -525.58M | -842.05M | -1.04B | -787.31M |
| Financing Cash Flow | -194.50M | -194.50M | 91.18M | 197.50M | 388.60M | 209.47M |
Ryman Healthcare Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:RYM, the sentiment is Positive. The current price of 1.88 is above the 20-day moving average (MA) of 1.83, above the 50-day MA of 1.86, and below the 200-day MA of 2.13, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 54.78 is Neutral, neither overbought nor oversold. The STOCH value of 50.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NZ:RYM.
Ryman Healthcare Peers Comparison
Overall Rating
NZ:SUM66Neutral
NZ:PHL63Neutral
NZ:TAH58Neutral
NZ:RAD56Neutral
NZ:RYM56Neutral
NZ:OCA50Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 66Neutral | NZD 1.46B | 4.62 | 8.89% | 2.86% | 14.09% | -18.30% | |
| 63Neutral | NZD 33.62M | 0.03 | ― | ― | 15.19% | 1154.17% | |
| 58Neutral | NZD 37.83M | 11.70 | ― | 4.21% | 21.56% | 18.96% | |
| 56Neutral | NZD 113.39M | 10.18 | ― | 6.03% | 9.76% | -1.75% | |
| 56Neutral | NZD 1.91B | -11.19 | -4.17% | ― | 11.86% | 72.99% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | NZD 449.02M | -64.52 | -0.57% | ― | 1.25% | -117.68% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NZ:RYM | Ryman Healthcare | 1.88 | -0.99 | -34.49% | |
| NZ:OCA | Oceania Healthcare Ltd. | 0.62 | -0.20 | -24.39% | |
| NZ:SUM | Summerset Group Holdings Limited | 5.95 | -6.38 | -51.75% | |
| NZ:PHL | Promisia Healthcare Limited | 0.62 | 0.06 | 11.71% | |
| NZ:TAH | Third Age Health Services Limited | 3.80 | -1.61 | -29.77% | |
| NZ:RAD | Radius Residential Care Ltd | 0.40 | 0.02 | 4.99% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 05, 2026
